Abstract
Introduction Vaccination is considered one of the solutions to the COVID-19 pandemic. However, a small proportion of the population was fully vaccinated in Benin (20.9%) and Senegal (7.6%) by December 2022. This study explores the determinants of intent to vaccinate.
Methods This was a cross-sectional, descriptive, and analytical study of 865 Beninese and 607 Senegalese aged 18 years and older. Marginal quota sampling by age, gender and region was adopted. Data collection, using a survey instrument based on the Random Digit Dialing (RDD) method, was conducted from December 24, 2020, to January 16, 2021, in Senegal and from March 29 to May 14, 2021, in Benin. The questionnaire used the Theory of Planned Behavior (TPB) and the Health Belief Model (HBM). The influence of factors was tested using a structural equation model. All analyses were conducted in R.
Results Results show that a good perception of the benefits of vaccination (βsen =0.33***; βBen=0.12***), a positive attitude (βsen=0.22***; βBen=0.20***), and sensitivity to subjective norms (βsen=0.19***; βBen=0.32***) positively influence the intention to vaccinate. Low trust in health care providers (βsen=-0.40***; βBen=-0.36***) amplifies the perceived risk of vaccination (βsen=-0.14***; βBen=-0.25***), which negatively impacts intention to vaccinate. Perceived vaccine efficacy was affected by perceived risk (βsen=-0.12***; βBen=-0.05***) of the disease and improved by good apprehension of the benefits of vaccination (βsen=0.60***; βBen=0.13***). Aspects related to behavioral control, vaccine information seeking, efficacy, or fairness did not appear as correlates of vaccine intention (P>0.05).
Conclusion Beninese and Senegalese public health authorities could develop additional intervention strategies to improve immunization coverage by considering these influencing factors, the basis of which could be better understood through subsequent qualitative studies.
Competing Interest Statement
The authors have declared that no competing interests exist.
Clinical Trial
NA
Funding Statement
This research is part of the Support to the African Response to the COVID-19 Epidemic (ARIACOV : https://www.ariacov.org) program funded by the French Development Agency (AFD : https://www.afd.fr/fr).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research received approval from the National Health Research Ethics Committee of Senegal (SEN/20/23) and the Local Ethics Committee for Biomedical Research of the University of Parakou in Benin (0308/CLERB-UP/P/SP/R/SA).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data are included in the paper.
